124 related articles for article (PubMed ID: 21083246)
1. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
Oosterhuis B
Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
[No Abstract] [Full Text] [Related]
2. Microdosing: current and the future.
Lappin G
Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
[TBL] [Abstract][Full Text] [Related]
3. Microdosing in early lead discovery.
Jekunen AP; Pauwels EK; Kairemo KJ
Bioanalysis; 2010 Mar; 2(3):421-8. PubMed ID: 21083252
[TBL] [Abstract][Full Text] [Related]
4. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
5. New ultrasensitive detection technologies and techniques for use in microdosing studies.
Lappin G; Wagner CC; Langer O; van de Merbel N
Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
[TBL] [Abstract][Full Text] [Related]
6. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
[TBL] [Abstract][Full Text] [Related]
7. Microdosing for early biokinetic studies in humans.
Stenström K; Sydoff M; Mattsson S
Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
[TBL] [Abstract][Full Text] [Related]
8. Welcome to 'microdosing'.
Ings RM
Bioanalysis; 2010 Mar; 2(3):371-2. PubMed ID: 21083244
[No Abstract] [Full Text] [Related]
9. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
Bae SK; Shon JH
Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
[TBL] [Abstract][Full Text] [Related]
10. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
Lappin G; Garner RC
Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
[TBL] [Abstract][Full Text] [Related]
11. Opinion: Microdosing: safer clinical trials and fewer animal tests.
Langley G; Farnaud S
Bioanalysis; 2010 Mar; 2(3):393-5. PubMed ID: 21083249
[No Abstract] [Full Text] [Related]
12. Can positron emission tomography facilitate paediatric drug development?
Zimmer L
Fundam Clin Pharmacol; 2008 Dec; 22(6):595-8. PubMed ID: 19049660
[TBL] [Abstract][Full Text] [Related]
13. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
Soares HD
Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
[TBL] [Abstract][Full Text] [Related]
14. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
Chen G; Warrack BM; Goodenough AK; Wei H; Wang-Iverson DB; Tymiak AA
Drug Discov Today; 2011 Jan; 16(1-2):58-64. PubMed ID: 21093608
[TBL] [Abstract][Full Text] [Related]
15. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
[TBL] [Abstract][Full Text] [Related]
16. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
Palucki M; Higgins JD; Kwong E; Templeton AC
J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
[No Abstract] [Full Text] [Related]
17. [Utility of a microdose study for drug discovery and development].
Yamaura Y
Nihon Yakurigaku Zasshi; 2013 Mar; 141(3):126-30. PubMed ID: 23470476
[No Abstract] [Full Text] [Related]
18. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and biomeasures: key enablers for pharmacokinetic-pharmacodynamic modeling in drug discovery and development.
Agoram BM; van der Graaf PH
Bioanalysis; 2012 Jun; 4(10):1143-5. PubMed ID: 22651555
[No Abstract] [Full Text] [Related]
20. Positron emission tomography for use in microdosing studies.
Wagner CC; Müller M; Lappin G; Langer O
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
